Research

Providence Brain and Spine Institute

PDF

Clinical Study Results: Efficacy of vagal nerve stimulation on selected patients with intractable epilepsy

Diana Moses R.N., C.N.S., M.S., C.N.R.N.; Mark Yerby M.D., M.P.H., F.A.A.N., James Schimshock M.D.
Providence Epilepsy Services, Portland, Oregon

Vagal nerve stimulation (VNS) is an adjunctive therapy for improving seizure control in patients with epilepsy. The actual mechanism for how the VNS prevents seizures is not precisely known.

More »

Clinical trials: ALS

View current clinical trials investigating treatments for ALS.

More »

Clinical trials: Alzheimer’s disease

View current clinical trials investigating treatments for Alzheimer’s disease. More »

Clinical trials: Multiple sclerosis

Useful therapies are available for virtually every patient with multiple sclerosis. FDA-approved medications currently in use have had major beneficial impact on disease activity in many patients, but we must do better. We must develop therapies with even more potency in disease control, less potential of toxicity and improved ease of administration and patient comfort. More »

Clinical trials: Stroke

View current clinical trials investigating treatments for stroke. More »

Neurointerventional

More »

PDF

New Emergency Treatments for Stroke

Thrombolytic or "clot-busting" drugs offer an emergency treatment option for some people who are having a stroke. These medications, which include an agent called a tissue plasminogen activator (t-PA), halt the stroke by dissolving the blood clot that is blocking blood flow to the brain. More »

Sustained Long Term Use of Interferon Beta-1a in Patients with Relapsing MS

Although controlled clinical trials have established the efficacy of IFNB for the treatment of RMS, most studies are of comparatively short duration. Other long-term open-label extensions are often compromised by high attrition and incomplete clinical information. Further-more, few studies have evaluated long-term efficacy of IFNB in a large community-based cohort of RMS patients. More »

The Experimental treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Purpose of study:  To determine if Nuedexta exerts a palliative effect on speech, swallowing and salivation in patients with ALS.

Principal Investigator:  Dr. Kimberly Goslin
Contact:  Providence ALS Research Nurse at 503 962-1171

Sponsor:  ALS Association (ALSA) and the Northeast ALS Consortium (NEALS) More »

PDF

The Pacific Northwest MS Registry: Year 4 Update and Diagnosis Validation

Accurate measures of MS prevalence in the Pacific Northwest United States were lacking. The Pacific Northwest MS Registry was established by the Providence MS Center and the National MS Society Oregon Chapter in 2007 to assess geographic distribution, access to medical care and treatment for MS, as well as unique characteristics of the MS population in this region. More »

Vascular intervention

More »